logo
US doctors link microplastics to premature births

US doctors link microplastics to premature births

Yahoo31-01-2025
Microplastics and nanoplastics are more likely to show up in the placentae of premature babies than those born full-term, according to a team of US-based doctors.
The discovery means there is a "possibility" that the plastic shards "could be contributing to the risk and occurrence of preterm birth," according to Kjersti Aagaard of Boston Children's Hospital.
Microplastics are smaller than 5 millimetres, while nanoplastics are too tiny to be seen by the human eye. In recent years they have been found in male reproductive organs and have been shown to pass from mother to unborn baby.
"When combined with other recent research, this study adds to the growing body of evidence, ranging from heart disease to potentially stroke, that demonstrates a real risk of exposure to plastics on human health and disease," said Aagaard.
"The finding of higher placental concentrations among preterm births was surprising because it was counter-intuitive to what you might expect if it was merely a byproduct of the length of time of the pregnancy," said Enrico Barrozo of Baylor College of Medicine and Texas Children's Hospital in Houston.
The team's research was based on "highly sensitive" mass spectrometry analysis of 175 placentae; 100 of which were at term and 75 collected preterm or at less than 37 weeks of pregnancy. It was published in the medical journal Pregnancy and presented at the Society for Maternal-Fetal Medicine's annual meeting on January 30.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

US pediatricians' new COVID-19 shot recommendations differ from CDC advice
US pediatricians' new COVID-19 shot recommendations differ from CDC advice

Boston Globe

timean hour ago

  • Boston Globe

US pediatricians' new COVID-19 shot recommendations differ from CDC advice

'It is going to be somewhat confusing. But our opinion is we need to make the right choices for children to protect them,' he added. The AAP is strongly recommending COVID-19 shots for children ages 6 months to 2 years. Shots also are advised for older children if parents want their kids vaccinated, the AAP said. Advertisement That differs from guidance established under US Health Secretary Robert F. Kennedy Jr., which doesn't recommend the shots for healthy children of any age but says kids may get the shots in consultation with physicians. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up Children ages 6 months to 2 years are at high risk for severe illness from COVID-19, and it was important that recommendations continue to emphasize the need for them to get vaccinated, said Campbell, a University of Maryland infectious diseases expert. Vaccinations also are recommended for older children who have chronic lung diseases or other conditions that put them at higher risk for severe disease, the AAP said. In a statement, Department of Health and Human Services spokesperson Andrew Nixon said 'the AAP is undermining national immunization policymaking with baseless political attacks.' He accused the group of putting commercial interests ahead of public health, noting that vaccine manufacturers have been donors to the AAP's Friends of Children Fund. The fund is currently paying for projects on a range of topics, including health equity and prevention of injuries and deaths from firearms. Advertisement The 95-year-old Itasca, Illinois-based organization has issued vaccination recommendations for children since the 1930s. In 1995, it synced its advice with recommendations made by the federal government's Centers for Disease Control and Prevention. There have been a few small differences between AAP and CDC recommendations since then. For example, the AAP has advised that children get HPV vaccinations starting at age 9; the CDC says that's OK but has emphasized vaccinations at ages 11 and 12. But in 30 years, this is the first time the recommendations have differed 'in a significant or substantial way,' Campbell said. Until recently, the CDC — following recommendations by infectious disease experts — has been urging annual COVID-19 boosters for all Americans ages 6 months and older. But in May, US Health Secretary Robert F. Kennedy Jr. announced that COVID-19 vaccines are no longer recommended for healthy children and pregnant women. A few days later, the CDC issued language that healthy children may get the shots, but that there was no longer a 'should' recommendation. The idea that healthy older kids may be able to skip COVID-19 boosters has been brewing for some time among public health experts. As the COVID-19 pandemic has waned, experts have increasingly discussed the possibility of focusing vaccination efforts on people 65 and older — who are among those most as risk for death and hospitalization. A CDC expert panel in June was set to make recommendations about the fall shots. Among the options the panel was considering was whether suggest shots for high-risk groups but still giving lower-risk people the choice to get vaccinated. Advertisement But Kennedy bypassed the group, and also decided to dismiss the 17-member panel and appoint his own, smaller panel, that included vaccine skeptics. Kennedy also later excluded the AAP, the American Medical Association and other top medical organizations from working with the advisers to establish vaccination recommendations. Kennedy's new vaccine panel has yet to vote on COVID-19 shot recommendations. The panel did endorse continuing to recommend fall flu vaccinations, but also made a decision that led to another notable difference with the AAP. The new advisory panel voted that people should only get flu vaccines that are packaged as single doses and do not contain the preservative thimerosal. The AAP said there is no evidence of harm from the preservative, and recommended doctors use any licensed flu vaccine product that's appropriate for the patient.

Germany's Merck receives approval for cancer drug after takeover deal
Germany's Merck receives approval for cancer drug after takeover deal

Yahoo

timean hour ago

  • Yahoo

Germany's Merck receives approval for cancer drug after takeover deal

The European Commission has granted German pharmaceutical giant Merck approval to use the cancer drug Ogsiveo, the Darmstadt-based firm said on Monday. The drug is approved as a therapy for the treatment of rare soft tissue tumours in adults. Ogsiveo is the first and only therapy approved in the EU for the treatment of so-called desmoid tumours. The drug was developed by US biopharmaceutical company Springworks Therapeutics, which Merck only acquired in July for around €3 billion ($3.5 billion), the largest acquisition in Merck's pharmaceuticals business in almost 20 years. Desmoid tumours are rare, locally aggressive tumours that grow in the connective tissue of the body. According to the figures, around 1,300 to 2,300 new cases are diagnosed in the EU every year. The tumours can lead to severe pain, restricted mobility and severe, persistent fatigue and are difficult to treat. Ogsiveo is already on the market in the United States. Merck acquired Springworks in the expectation that the company would also receive marketing authorization in the EU. Merck chief executive Belén Garijo hopes that Ogsiveo will become a blockbuster drug and generate annual sales of at least $1 billion for the group, she told dpa in July. Merck's pharmaceutical division - with drugs for cancer, infertility and multiple sclerosis - has seen solid growth recently. However, the company is under pressure to bring new drugs onto the market. Several promising drugs have failed in clinical trials. Merck recently had to lower its sales targets in several divisions following a weak second quarter. Merck shares have recently performed weakly. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics
Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics

Yahoo

time2 hours ago

  • Yahoo

Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics

Biodesix recently validated Thermo Fisher's tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer LOUISVILLE, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leader in personalized diagnostics, announced that the company is designated as a Thermo Fisher Scientific Center of Excellence (COE) as part of Thermo Fisher's collaborative initiative to advance NGS-based diagnostics. The services provided to Thermo Fisher are an example of Biodesix Development Services offerings, including customizable options that enable the world's leading life sciences companies, biopharmaceutical, and medical research institutions with scientific, technological, and operational capabilities. As Thermo Fisher announced in July 2025, Biodesix was an instrumental partner in the validation of the Oncomine Dx Express Test leading to the FDA approval of the Genexus Dx Integrated Sequencer. Biodesix Development Services conducted validation studies utilizing its design-controlled laboratory processes, quality management systems, and contributed data generation in support of regulatory submission. 'Working with Thermo Fisher, we continue to forge a path to conquer cancer, and we are delighted to expand our molecular diagnostic and NGS testing capabilities in tissue-based profiling,' said Scott Hutton, CEO at Biodesix. "Being a member of Thermo Fisher's COE network puts us in excellent company with other global groups committed to transforming cancer diagnosis and care. We are excited about the potential to offer the Oncomine Dx Express Test in the future.' Upcoming presentations to learn more about the Thermo Fisher NGS precision oncology solution and how Biodesix will apply the science for its industry clients and healthcare professionals: August 27, 2025 | CAP TODAY | Thermo Fisher Scientific Webinar: Introduction of new FDA approved rapid NGS solution for Companion Diagnostics & tumor profiling in oncology. Speakers: David Chi, PhD, Thermo Fisher Scientific, Bence Sipos, MD, and Gary Pestano, PhD, Chief Development Officer, Biodesix September 15, 2025 | Orlando, FL | College of American Pathologists (CAP) 2025 Annual Meeting | Thermo Fisher-sponsored Panel: "Introduction of new IVD solution for rapid NGS profiling in Oncology". Speakers: Mahmoud Elsayad, MD, FCAP, University of Texas Health, Alison Roos, Thermo Fisher Scientific, and Gary Pestano, PhD, Chief Development Officer, Biodesix About Biodesix:Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world's leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit About the Thermo Fisher COE Network: Thermo Fisher's NGS COE Network partners with leading global institutions to develop, validate, and refine its Ion Torrent™ Oncomine™ solutions portfolio. Through these COEs, Thermo Fisher collaborates with experts to accelerate oncology research, foster strategic alliances, and advance precision medicine. Biodesix Contacts: Media:Natalie St. Denis, Director Corporate Communications, 925-9285 Investors:Chris Brinzey, Partner, 970-2843Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store